Surgery Partners (SGRY) to Announce Quarterly Earnings on Monday

Key Points

• Surgery Partners is expected to report Q2 2026 earnings before the market opens on August 10, with analysts forecasting EPS of $0.0579 and revenue of $830.03 million.
• In its prior quarter, the company reported a loss of $0.03 per share but exceeded analyst expectations, while revenue rose 4.5% year over year to $810.90 million.
• Analyst sentiment is generally positive, with a consensus “Moderate Buy” rating and an average price target of $21.60, compared with the stock’s recent price of $15.40.

Surgery Partners (NASDAQ:SGRY - Get Free Report) is expected to post its Q2 2026 results before the market opens on Monday, August 10th. Analysts expect Surgery Partners to announce earnings of $0.0579 per share and revenue of $830.03 million for the quarter. Individuals can check the company's upcoming Q2 2026 earning report for the latest details on the call scheduled for Monday, August 10, 2026 at 8:30 AM ET.

Surgery Partners (NASDAQ:SGRY - Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.12. The business had revenue of $810.90 million during the quarter, compared to analyst estimates of $797.69 million. Surgery Partners had a negative net margin of 2.28% and a positive return on equity of 1.04%. The company's quarterly revenue was up 4.5% on a year-over-year basis. During the same period in the previous year, the business posted $0.04 EPS. On average, analysts expect Surgery Partners to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Surgery Partners Price Performance

SGRY opened at $15.40 on Monday. The company has a quick ratio of 1.69, a current ratio of 1.86 and a debt-to-equity ratio of 1.17. The company's 50-day moving average price is $15.23 and its 200 day moving average price is $14.44. Surgery Partners has a fifty-two week low of $11.41 and a fifty-two week high of $24.10. The firm has a market cap of $2.01 billion, a price-to-earnings ratio of -25.67, a price-to-earnings-growth ratio of 4.60 and a beta of 1.92.

Institutional Investors Weigh In On Surgery Partners

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Surgery Partners by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 45,693 shares of the company's stock valued at $1,085,000 after purchasing an additional 2,015 shares in the last quarter. Millennium Management LLC increased its position in shares of Surgery Partners by 1,253.7% during the 1st quarter. Millennium Management LLC now owns 202,274 shares of the company's stock valued at $4,804,000 after purchasing an additional 219,806 shares during the period. Empowered Funds LLC raised its stake in shares of Surgery Partners by 11.0% in the 1st quarter. Empowered Funds LLC now owns 12,853 shares of the company's stock worth $305,000 after buying an additional 1,278 shares in the last quarter. Prudential Financial Inc. bought a new stake in shares of Surgery Partners in the 2nd quarter worth $219,000. Finally, Invesco Ltd. lifted its holdings in shares of Surgery Partners by 7.4% in the second quarter. Invesco Ltd. now owns 1,683,311 shares of the company's stock valued at $37,420,000 after buying an additional 115,627 shares during the period.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on SGRY. Zacks Research upgraded Surgery Partners from a "hold" rating to a "strong-buy" rating in a research report on Thursday, June 4th. Jefferies Financial Group restated a "buy" rating and set a $17.00 price objective on shares of Surgery Partners in a research report on Wednesday, May 6th. Finally, Weiss Ratings restated a "sell (e+)" rating on shares of Surgery Partners in a research note on Tuesday, May 26th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Surgery Partners currently has a consensus rating of "Moderate Buy" and an average price target of $21.60.

Surgery Partners Company Profile

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.